A lack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab

Retina

Volumn 32, Issue 7, 2012, Pages 1295-1301

  Wehrli, Sarah J ^a   Tawse, Kirstin ^a   Levin, Marc H ^a   Zaidi, Ali ^a   Pistilli, Maxwell ^a   Brucker, Alexander J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

age related macular degeneration; anti VEGF drug; bevacizumab; choroidal neovascularization; intraocular pressure; intravitreal injection; ranibizumab; toxicity

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

AGED; ARTICLE; CONTROLLED STUDY; EXUDATIVE MACULAR DEGENERATION; FEMALE; HUMAN; INCIDENCE; INTRAOCULAR HYPERTENSION; MAJOR CLINICAL STUDY; MALE; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG THERAPY, COMBINATION; EXUDATES AND TRANSUDATES; FEMALE; GLAUCOMA; HUMANS; INCIDENCE; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MALE; OCULAR HYPERTENSION; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WET MACULAR DEGENERATION;

EID: 84862860481     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31823f0c95     Document Type: Article

References (19)

1. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444. (Pubitemid 44511558)
2. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR Study. Ophthalmology 2009;116:57-65.
3. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431. (Pubitemid 44511557)
4. Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010;117:1124-1133.
5. Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcin-olone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064-1077.
6. Kim JE, Mantravadi AV, Hur EY, Covert DJ. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol 2008;146:930-933.
7. Wu H, Chen TC. The effects of intravitreal ophthalmic medications on intraocular pressure. Semin Ophthalmol 2009;24: 100-105.
8. Bakri SJ, McCannel CA, Edwards AO, Moshfeghi DM. Persistent ocular hypertension following intravitreal ranibizumab. Graefes Arch Clin Exp Ophthalmol 2008;246:955-958.
9. Kahook MY, Kimura AE, Wong LJ, et al. Sustained elevation in intraocular pressure associated with intravitreal bevacizu-mab injections. Ophthalmic Surg Lasers Imaging 2009;40: 293-295.
10. Adelman RA, Zheng Q, Mayer HR. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J Ocul Pharmacol Ther 2010;26:105-110.
11. Good TJ, Kimura AE, Mandava N, Kahook MY. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol 2011;95:1111-1114.
12. Zeger SC, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics 1988; 44:1049-1060. (Pubitemid 19026037)
13. Wei LJ, Lin DY, Weissfeld L. Regression analysis of multi-variate incomplete failure time data by using the marginal distribution. J Am Stat Assoc 1989;84:1065-1073.
14. Kernt M, Weige-Lüssenu, Yu M, et al. Bevacizumab is not toxic to human anterior-and posterior-segment cultured cells [German]. Ophthalmologe 2007;104:965-971.
15. Liu L, Ammar DA, Ross L, et al. Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibi-zumab: effects of long-term storage and product mishandling. Invest Ophthalmol Vis Sci 2011;52:1023-1034.
16. Kahook MY, Liu L, Ruzycki P, et al. High-molecular-weight aggregates in repackaged bevacizumab. Retina 2010;30: 887-892.
17. Bakri SJ, Ekdawi NS. Intravitreal silicone oil droplets after intravitreal drug injections. Retina 2008;28:996-1001.
18. Tseng JJ, Vance SK, Della Torre KE, et al. Sustained increased intraocular pressure related to intravitreal anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration. J Glaucoma 2011. March 16 [Epub ahead of print].
19. Kempen JH. Appropriate use and reporting of uncontrolled case series in the medical literature. Am J Ophthalmol 2011; 151:7-10.